Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

Landovitz, Raphael J.Li, Sue.Grinsztejn, Beatriz.Dawood, Halima.Liu, Albert Y.Magnus, Manya.Hosseinipour, Mina C.Panchia, Ravindre.Cottle, Leslie.Chau, Gordon.Richardson, Paul.Marzinke, Mark Albert.Hendrix, Craig W.Eshleman, Susan H.Zhang, Yinfeng.Tolley, Elizabeth E.Sugarman, Jeremy.Kofron, Ryan.Adeyeye, Adeola.Burns, David.Rinehart, Alex R.Margolis, David.Spreen, William R.Cohen, Myron S.McCauley, Marybeth.Eron, Joseph J.2019-12-152019-12-1520182018Landovitz, R.J., Li, S., Grinsztejn, B., Dawood, H., Liu, A.Y., Magnus, M., Hosseinipour, M.C., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M., Hendrix, C.W., Eshleman, S.H., Zhang, Y., Tolley, E., Sugarman, J., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A.R., Margolis, D., Spreen, W.R., Cohen, M.S., McCauley, M.and Eron, J.J. 2018. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Medicine 15(11), e1002690.http://dx.doi.org/10.1371/journal.pmed.1002690https://researchspace.ukzn.ac.za/handle/10413/16641CAPRISA, 2018.Abstract available in pdf.enAdolescent.Adult.Anti-HIV Agents/adverse effects.Anti-HIV Agents/blood.Anti-HIV Agents/pharmacokinetics.Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.Article